Revenue at NightHawk Radiology Holdings jumped 79% in the third quarter, reflecting teleradiology acquisitions as well as a 24% growth in organic operations. Investors were nonplussed, however, by a drop in profit and lowered guidance for revenue and net for the full year 2007. This caused the share price to dip about $0.60 at the market open to $22.98.
Revenue at NightHawk Radiology Holdings jumped 79% in the third quarter, reflecting teleradiology acquisitions as well as a 24% growth in organic operations. Investors were nonplussed, however, by a drop in profit and lowered guidance for revenue and net for the full year 2007. This caused the share price to dip about $0.60 at the market open to $22.98.
Revenue grew to a record $45.2 million compared with $25.2 million in the third quarter 2006. Net income dropped, however, to $3.8 million from $5.6 million in the year earlier period on higher expenses associated with corporate acquisitions, stock compensation, and other liabilities. The company stood by its 2008 guidance of between $215 and $225 million in revenue and $1.31 to $1.36 in adjusted earnings per diluted share.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.